FOXP3 and glioblastoma: (2013) (98) demonstrated that an EGFRvIII-specific bispecific T-cell engager (BiTE) could redirect human CD4+CD25+CD127dim/- Foxp3+ Treg and activate them in the presence of glioblastoma tumors expressing EGFRvIII.